What is the 13F Pro Quality Score for DTIL?

13F Pro ranks PRECISION BIOSCIENCES INC (DTIL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DTIL's current score at https://13fpro.ai/research/DTIL (free sign-up required for the full ranking).

Which hedge funds own the most DTIL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DTIL include Octagon Capital Advisors, abrdn plc, Empery Asset Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DTIL as soon as new 13F filings post.

Where does 13F Pro source DTIL data?

All PRECISION BIOSCIENCES INC fundamentals and ownership data come directly from SEC EDGAR. PRECISION BIOSCIENCES INC files with the SEC under CIK 1357874. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DTIL in?

PRECISION BIOSCIENCES INC (DTIL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DTIL research updated on 13F Pro?

DTIL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRECISION BIOSCIENCES INC(DTIL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1357874 DTIL stock profile & AI dashboard →

13F Pro Quality Score

3.9/100

Rank #2,856 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

0.6/100

Profitability

2.8/100

Balance Sheet

2.7/100

Earnings Quality

30.0/100

Free Cash Flow

2.8/100

Institutional Flow

0.5/100

Revenue Scale

3.7/100

Dilution Risk

6.6/100

DTIL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PRECISION BIOSCIENCES INC (DTIL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DTIL at 3.9/100 on a 32-signal composite quality model, placing it at rank #2,856 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (0.5) and revenue growth (0.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), PRECISION BIOSCIENCES INC reports quarterly revenue of $10.8M, net income of $-18.4M, free cash flow of $-12.0M. Top institutional holders of DTIL by reported 13-F value include Octagon Capital Advisors, abrdn plc, Empery Asset Management,, based on the most recent SEC filings. DTIL trades on the Nasdaq exchange and files with the SEC under CIK 1357874. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DTIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECISION BIOSCIENCES INC directly from SEC EDGAR. PRECISION BIOSCIENCES INC's 13F Pro composite quality score has ranged between 4 and 58 since 2021, currently 3.9 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about PRECISION BIOSCIENCES INC

Quirks, history, and lore behind DTIL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Revenue is modest — this is a clinical-stage company burning cash in pursuit of breakthroughs, with a market cap that has swung wildly in the hundreds of millions range.
3
The History
Founded in the 2010s, it was built around a proprietary take on genome editing — the hottest corner of biotech — and went public to fund its pipeline.
4
The Secret
Rather than licensing CRISPR from the academic giants, the company developed its own arcus nuclease platform — a distinct gene-editing engine it calls entirely its own.
5
The Lore
Its pipeline spans two ambitious fronts: ex vivo cell therapies for blood cancers and in vivo gene editing delivered directly into the body — essentially rewriting DNA as medicine.
6
The Giveaway
Its ticker spells out DTIL, its name shouts precision, and its Durham lab is quietly trying to edit its way to cures one nuclease cut at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$10.8M

Net Income

Q1 2026

$-18.4M

Free Cash Flow

Q1 2026

$-12.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-50.1% YoY

$34.3MFY 2025

FY21 $115.5MFY22 $25.1MFY24 $68.7MFY25 $34.3M

Net Income

-738.0% YoY

$-45.7MFY 2025

FY21 $-30.6MFY22 $-111.6MFY24 $7.2MFY25 $-45.7M

Operating Income

-99.3% YoY

$-52.1MFY 2025

FY21 $-39.4MFY22 $-62.3MFY24 $-26.2MFY25 $-52.1M

EPS (Diluted)

-784.6% YoY

$-3.56FY 2025

FY21 $-0.26FY22 $-0.64FY24 $0.52FY25 $-3.56

Total Assets

+13.2% YoY

$154.4MFY 2025

FY21 $211.5MFY22 $238.2MFY24 $136.4MFY25 $154.4M

Total Debt

—FY 2025

FY21 $2.5MFY22 $22.2MFY24 —FY25 —

Op. Cash Flow

-12.7% YoY

$-65.8MFY 2025

FY21 $-10.9MFY22 $-45.8MFY24 $-58.4MFY25 $-65.8M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$34.3M -50.1%	$68.7M +173.7%	$25.1M -78.3%	$115.5M +375.7%	$24.3M -97.7%	$1.07B
Net Income	$-45.7M -738.0%	$7.2M +106.4%	$-111.6M -264.8%	$-30.6M +71.9%	$-109.0M -17.4%	$-92.9M
Operating Income	$-52.1M -99.3%	$-26.2M +58.0%	$-62.3M -58.2%	$-39.4M +64.1%	$-109.8M -25.9%	$-87.2M
EPS (Diluted)	$-3.56 -784.6%	$0.52 +181.9%	$-0.64 -143.9%	$-0.26	—	—
Total Assets	$154.4M +13.2%	$136.4M -42.7%	$238.2M +12.6%	$211.5M +40.9%	$150.2M -36.2%	$235.2M
Total Debt	—	—	$22.2M +796.8%	$2.5M	—	—
Operating Cash Flow	$-65.8M -12.7%	$-58.4M -27.7%	$-45.8M -321.6%	$-10.9M +87.6%	$-87.4M -23.1%	$-71.0M

AI Insight: DTIL Financial Trends

DTIL burns through equity at ~$15M/quarter but a $34M Q4 2025 revenue spike temporarily reversed losses; sustainability of that event is the critical question.

• Revenue collapsed from $50M in Q2 2024 to near-zero for four consecutive quarters before a $34M Q4 2025 windfall, then fell to $11M in Q1 2026.

• Equity eroded steadily from $75M in Q2 2024 to $17M in Q3 2025, partially recovering to $92M in Q4 2025 before falling back to $76M in Q1 2026.

• Operating cash flow has been negative every quarter, ranging from -$6M to -$20M, with no sign of operational self-sufficiency.

⚠ Q4 2025 revenue spike to $34M appears one-time; Q1 2026 dropped back to $11M with a -$18M net loss — recurring revenue visibility is near zero.

⚠ Equity of $76M at Q1 2026 supports roughly 4–5 quarters at current burn; no debt data available to assess additional liquidity buffer.

⚠ Any follow-on partnership or licensing deal similar to Q4 2025's event would be a key positive inflection to monitor.

AI Insight: DTIL Ratio Trends

DTIL's profitability is highly episodic — Q4 2025 positive margins collapsed sharply in Q1 2026, revealing an unsustainable earnings base.

• OpMargin swung from +36.6% in Q4 2025 to -83.7% in Q1 2026, signaling Q4 gains were likely one-time in nature.

• ROA has deteriorated from +79.0% in Q2 2024 to -51.3% in Q1 2026, reflecting persistent asset inefficiency.

• TTM OpMargin of -86.8% and NPM of -96.7% confirm the business burns cash on a trailing basis despite periodic bright spots.

⚠ Whether Q4 2025's +54.2% ROIC and +87.3% ROE recur — single-quarter spikes with no D/E data make sustainability unclear.

⚠ ROE collapsed from +87.3% in Q4 2025 to -96.9% in Q1 2026 — equity base erosion risk if losses continue.

Get alerted when DTIL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRECISION BIOSCIENCES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DTIL

Octagon Capital Advisors LP
$12.3M2,236,732 sh
abrdn plc
$12.3M2,230,178 sh
Empery Asset Management, LP
$10.8M1,968,879 sh
Bleichroeder LP
$9.1M1,662,500 sh
BOOTHBAY FUND MANAGEMENT, LLC
$5.9M1,066,050 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$5.5M995,371 sh
Lynx1 Capital Management LP
$5.4M985,113 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.0M910,740 sh
Affinity Asset Advisors, LLC
$3.3M597,946 sh
MARSHALL WACE, LLP
$2.3M415,671 sh

Fund	Value	Shares
Octagon Capital Advisors LP	$12.3M	2,236,732
abrdn plc	$12.3M	2,230,178
Empery Asset Management, LP	$10.8M	1,968,879
Bleichroeder LP	$9.1M	1,662,500
BOOTHBAY FUND MANAGEMENT, LLC	$5.9M	1,066,050
DRIEHAUS CAPITAL MANAGEMENT LLC	$5.5M	995,371
Lynx1 Capital Management LP	$5.4M	985,113
VANGUARD CAPITAL MANAGEMENT LLC	$5.0M	910,740
Affinity Asset Advisors, LLC	$3.3M	597,946
MARSHALL WACE, LLP	$2.3M	415,671

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DTIL on your watchlist

Track score changes the day PRECISION BIOSCIENCES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DTIL a good stock to buy?

13F Pro's AI-powered analysis of PRECISION BIOSCIENCES INC (DTIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DTIL are available on the DTIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DTIL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DTIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRECISION BIOSCIENCES INC's investment landscape.